Bevacizumab (Avastin)

References

1. 1.↵
   1. Ferrara N

   . Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581–611

   CrossRefPubMedWeb of Science
2. 2.↵
   Genentech, Inc. United States Securities and Exchange Commission. http://www.sec.gov/Archives/edgar/data/318771/000031877109000003/form10-k_2008.htm. Accessed October 6, 2009
3. 3.↵
   1. Hicklin DJ,
   2. Ellis LM

   . Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–27

   Abstract/FREE Full Text
4. 4.↵
   Bevacizumab. Wikipedia. http://en.wikipedia.org/wiki/Bevacizumab. Accessed October, 6, 2009
5. 5.↵
   1. Daniele G,
   2. Marciano R,
   3. Tortora G

   . The role of bevacizumab in breast cancer. Eur J Cancer 2008;6(suppl):26–29
6. 6.↵
   1. Mukhopadhyay D,
   2. Datta K

   . Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol 2004;14:123–30

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Presta LG,
   2. Chen H,
   3. O'Connor SJ,
   4. et al

   . Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593–99

   Abstract/FREE Full Text
8. 8.↵
   1. Yuan F,
   2. Chen Y,
   3. Dellian M,
   4. et al

   .. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765–70

   Abstract/FREE Full Text
9. 9.↵
   1. Willett CG,
   2. Boucher Y,
   3. di Tomaso E,
   4. et al

   . Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145–47

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Gerber HP,
    2. Ferrara N

    . Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671–80

    Abstract/FREE Full Text
11. 11.↵
    1. Borgström P,
    2. Hillan KJ,
    3. Sriramarao P,
    4. et al

    . Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032–39

    Abstract/FREE Full Text
12. 12.↵
    1. Borgström P,
    2. Bourdon MA,
    3. Hillan KJ,
    4. et al

    . Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998;35:1–10

    CrossRefPubMedWeb of Science